Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Ortho Extremities/Soft-Tissue Repair Market To Grow $2.2 Billion By 2019

Executive Summary

The US market for orthopedic extremities and soft-tissue repair products will grow by $2.2 billion over the next five years, according to a global market report from Medtech Insight. Major factors contributing to the strong growth of this market include: the expanding elderly demographic, an increase in the number of active adults who are prone to physical injuries, and improvements in biological material and implants that reduce complications and improve quality of life.

You may also be interested in...



Market Intel: Orthobiologics Market Well-Positioned For Innovative Reconstruction

Global sales of orthobiologics for musculoskeletal soft tissue replacement and regeneration are predicted to hit $1.4bn by 2021, driven largely by rising numbers of sports injuries requiring treatment, but also by a higher prevalence of osteoarthritis and a need for innovative treatments for musculoskeletal repair. This article offers an in-depth look at the orthobiologics market landscape for cartilage, meniscus and ligament/tendon replacement and regeneration, as well as insight from an orthopedic surgeon. It also analyzes key players in these markets and highlights emerging trends and the greatest barriers for wider adoption of products.

Earnings Winners & Losers: QGEN, WMGI, ALR, SN, and LIVN

Diagnostics, orthopedics, and cardiovascular device companies are among those that wait until November to report their results for the quarter that ended at the end of September. Medtech Insight’s Earnings Winners & Losers highlights some of the companies that had news to celebrate, and a few that were disappointed with the quarter.

Wright Sees Potential $1B+ Market Opportunity With Newly-Approved Orthobiologic

The Augment biologic-based device was approved for use in ankle and hindfoot fusions after overcoming multiple regulatory challenges, opening up a $300 million US market opportunity. It's the first indication for a product platform that Wright hopes to extend to use in soft-tissue procedures such as rotator cuff or tennis elbow repair, which represent a $1 billion-plus opportunity.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel